Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 676

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 676
---
 as

<div align='center'>440</div>

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION estimated immediately after the Mergers, TuHURA Biosciences, Inc. stockholders will own approximately 92.7% of the TuHURA Common Stock outstanding following the Closing and Kineta stockholders will own approximately 7.3% of the TuHURA Common Stock outstanding, which could be adjusted further as the stock consideration to be issued as Merger Consideration is subject to adjustment in accordance with the Merger Agreement. The unaudited pro forma condensed combined financial information has been prepared to give pro forma effect with respect to both the reverse share split, as effected on October 18, 2024 for the Kintara Merger, as well as the additional issuance of shares and related transactions surrounding the Merger Consideration in the Mergers for Kineta shareholders.

|                                                                                  |     | Share Ownership 
 Post-Mergers    |            |     | Approx. 
 %       |       |   |
| TuHURA Biosciences, Inc. stockholders at the Effective Time of the Mergers(1)(2) |     |                 | 48,930,004 |     |         |  92.7 | % |
| Kineta, Inc. public stockholders at the Effective Time of the Mergers(3)         |     |                 |  3,868,635 |     |         |   7.3 | % |
| Pro Forma Common Stock                                                           |     |                 | 52,798,639 |     |         | 100.0 | % |

| (1) | Includes (i) 42,284,525 shares issued and outstanding to TuHURA common stockholders following the closing of the Kintara Merger, (ii) 297,029 shares underlying the penny warrants issued to underwriters in lieu of cash payment notes, as-converted upon their issuance, (iii) 1,395,871 shares issued and outstanding for those TuHURA warrant holders who exercised their warrants subsequent to closing of the Kintara Merger (consisting of 39,234 exercises prior to December 31, 2024 and 1,356,637 additional exercises subsequent to December 31, 2024), and (iv) 4,952,579 estimated shares issued in connection with the Concurrent Investment agreement which is a condition precedent to the